CVC Capital Partners, Temasek and Vatera Healthcare Partners have acquired a controlling stake in Alvogen from Pamplona Capital Management. Aztiq Pharma, led by Alvogen CEO Robert Wessman, will remain with a significant stake, as well as Pamplona with a small stake.
Alvogen's lines of business include: product development, contract manufacturing and research (CMO), and sales of generic medicines (Gx and Hx), biosimilars and OTCs. Its product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology in addition to a fast growing portfolio of biosimilars and OTC products.
Alvogen says it has delivered six consecutive years of strong revenue and profit growth. The company has regional hubs in North America, Eastern Europe and Asia Pacific. North America is its largest market with over 60 pipeline ANDA filings. The Group currently has more than 200 pharmaceutical projects in development and registrations and 350 marketed products.
“Alvogen has established itself as one of the fastest growing generic pharmaceutical companies in the industry, delivering double digit revenue and profit growth annually since 2009," says Robert Wessman, CEO of Alvogen. "The Group has transformed from being a domestic US business to a global player."
Read the full release